Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2022 Sep 30;77(10):2693-2700.
doi: 10.1093/jac/dkac256.

Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge

Nicholas Piccicacco  1 , Kristen Zeitler  1 , Austin Ing  2 , Jose Montero  3 , Jonathan Faughn  4 , Suzane Silbert  4 , Kami Kim  3   5
Affiliations
Controlled Clinical Trial

Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge

Nicholas Piccicacco et al. J Antimicrob Chemother. .

Abstract

Background: Remdesivir and sotrovimab both have clinical trial data in the outpatient setting demonstrating reduction in the risk of hospitalizations and emergency department (ED) visits related to COVID-19.

Objectives: To evaluate the effectiveness of remdesivir in comparison with sotrovimab and matched high-risk control patients in preventing COVID-19-related hospitalizations and ED visits during the Omicron B.1.1.529 surge.

Patients and methods: This retrospective cohort study included outpatients positive for SARS-CoV-2, with non-severe symptoms for ≤7 days and deemed high-risk for severe COVID-19 by an internal scoring matrix. Patients who received remdesivir or sotrovimab from 27/12/2021 to 04/02/2022 were included (n = 82 and n = 88, respectively). These were compared with a control cohort of high-risk COVID-19 outpatients who did not receive therapy (n = 90). The primary outcome was a composite of 29 day COVID-19-related hospitalizations and/or ED visits. Pre-specified secondary outcomes included components of the primary endpoint, 29 day all-cause mortality and serious adverse drug events.

Results: Patients treated with remdesivir were significantly less likely to be hospitalized or visit the ED within 29 days from symptom onset (11% versus 23.3%; OR = 0.41, 95% CI = 0.17-0.95). Patients receiving sotrovimab were also less likely to be hospitalized or visit the ED (8% versus 23.3%; OR = 0.28, 95% CI = 0.11-0.71). There was no difference in the incidence of hospitalizations/ED visits between sotrovimab and remdesivir.

Conclusions: Our highest-risk outpatients with Omicron-related COVID-19 who received early sotrovimab or remdesivir had significantly lower likelihoods of a hospitalization and/or ED visit.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Control cohort patient selection flow diagram.
Figure 2.
Figure 2.
Kaplan–Meier curve for primary outcome.
See this image and copyright information in PMC

References

    1. Johns Hopkins University . COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html.
    1. Zhu N, Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–33. 10.1056/NEJMoa2001017 - DOI - PMC - PubMed
    1. CDC . Underlying Medical Conditions Associated With Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Updated 15 June 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingco....
    1. Yek C, Warner S, Wiltz J et al. Risk factors for severe COVID-19 outcomes among persons aged ≥18 years who completed a primary COVID-19 vaccination series - 465 health care facilities, United States, December 2020-October 2021. MMWR Morb Mortal Wkly Rep 2022; 71: 19–25. 10.15585/mmwr.mm7101a4 - DOI - PMC - PubMed
    1. Planas D, Saunders N, Maes P et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 2022; 602: 671–7. 10.1038/s41586-021-04389-z - DOI - PubMed

Publication types